<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42999" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Zafirlukast</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhaliwal</surname>
            <given-names>Amareen</given-names>
          </name>
          <aff>Boston University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amareen Dhaliwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42999.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Zafirlukast belongs to the leukotriene receptor antagonist (LTRA) class of medications and is utilized for managing and treating chronic asthma.&#x000a0;The medication is available in&#x000a0;10 mg and 20 mg chewable tablets approved by the&#x000a0;U.S. Food and Drug Administration (FDA) for use in adults and children 5&#x000a0;or&#x000a0;older. Zafirlukast is also used as an off-label medication to manage chronic urticaria, prevent&#x000a0;exercise-induced bronchospasm, and treat allergic rhinitis.&#x000a0;As per the Global Initiative for Asthma (GINA) guidelines, LTRA, including montelukast or zafirlukast, is an essential controller therapy for patients who cannot tolerate inhaled corticosteroids (ICS). This activity reviews the mechanism of action, adverse event profile, indications, effects, contraindications, and other crucial factors relevant to utilizing zafirlukast as an agent in managing and prophylaxis of chronic asthma.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for zafirlukast therapy, including patients with chronic asthma or those in need of adjunctive treatment, where inhaled corticosteroids are not well-tolerated.</p></list-item><list-item><p>Screen patients for contraindications to zafirlukast, such as hypersensitivity reactions, hepatic impairment, and concurrent medications, which may impact the safe and effective use of the drug.</p></list-item><list-item><p>Assess the effectiveness of zafirlukast therapy in managing asthma symptoms and improving lung function, monitoring treatment response, and adjusting the treatment plan as necessary.</p></list-item><list-item><p>Collaborate with other healthcare professionals, such as respiratory therapists, pharmacists, and other healthcare providers, to ensure coordinated care and optimize zafirlukast therapy, including monitoring for adverse effects and interactions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42999&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42999">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42999.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Zafirlukast&#x000a0;belongs&#x000a0;to the&#x000a0;leukotriene receptor antagonist (LTRA) class of medications and is available&#x000a0;in strengths of 10 mg and 20 mg chewable tablets for oral administration. The U.S. Food and Drug Administration (FDA) approved the medication for managing chronic asthma in adults and children 5 or&#x000a0;older. Zafirlukast is also used as an off-label drug to manage chronic urticaria, prevent&#x000a0;exercise-induced bronchospasm, and treat allergic rhinitis in patients.<xref ref-type="bibr" rid="article-42999.r1">[1]</xref><xref ref-type="bibr" rid="article-42999.r2">[2]</xref>&#x000a0;</p>
        <p>LTRA, including montelukast or zafirlukast, is an essential controller therapy for patients who cannot tolerate inhaled corticosteroids (ICS) as per the Global Initiative for Asthma (GINA) guidelines.<xref ref-type="bibr" rid="article-42999.r3">[3]</xref></p>
        <p>A recent study indicates that TMEM16A, a membrane ion channel, is a potential drug target for treating lung adenocarcinoma. Zafirlukast can target the TMEM16A channel to inhibit the proliferation&#x000a0;and migration of cells associated with lung adenocarcinoma. Furthermore, in vivo experiments have demonstrated that zafirlukast effectively inhibits the growth of lung adenocarcinoma tumors in mice. The research&#x000a0;identified zafirlukast as a novel TMEM16A channel inhibitor with remarkable anticancer properties. Zafirlukast is a promising pharmaceutical candidate for forthcoming preclinical and clinical investigations in individuals with lung adenocarcinoma.<xref ref-type="bibr" rid="article-42999.r4">[4]</xref></p>
      </sec>
      <sec id="article-42999.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Zafirlukast, with an empirical formula C<sub>31</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S, belongs to the LTRA category and demonstrates a remarkable selectivity as a competitive antagonist of the cysteinyl leukotriene-1 receptor (CYSLTR1). Zafirlukast competes against the proinflammatory cysteinyl-leukotrienes C4, D4, and E4 (including LTC, LTD, and LTE) at CYSLTR1, effectively preventing leukotriene-induced inflammation. The interaction between leukotrienes and CYSLTR1 triggers inflammatory reactions associated with the underlying disease process&#x000a0;of asthma. Therefore, by competitively inhibiting proinflammatory leukotrienes, the result is a reduction in neutrophil and eosinophil migration, as well as the aggregation of neutrophils and monocytes, adhesion of leukocytes, airway edema, inflammation, and constriction of bronchial passages (see <bold>Image.</bold> Zafirlukast Mechanism of Action, Indications, and Contraindications).<xref ref-type="bibr" rid="article-42999.r5">[5]</xref></p>
        <p>Furthermore, zafirlukast acts as a selective receptor antagonist for leukotriene D4 and E4 (LTD4 and LTE4), which are constituents of the slow-reacting substance of anaphylaxis (SRSA).<xref ref-type="bibr" rid="article-42999.r6">[6]</xref><xref ref-type="bibr" rid="article-42999.r7">[7]</xref></p>
        <p>Zafirlukast inhibits bronchoconstriction triggered by various types of inhalational challenges. Administration of zafirlukast as a pretreatment effectively mitigated bronchoconstriction induced by cold air and sulfur dioxide in individuals with asthma. Pretreatment with the drug also attenuated the early- and late-phase reactions caused by inhaling antigens such as cat dander, ragweed, grass, and other allergens in individuals with asthma. Zafirlukast also mitigated the increase in bronchial hyperresponsiveness to inhaled histamine that followed the inhalation of allergens.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: Zafirlukast exhibits rapid absorption following oral administration of the drug, with the peak plasma concentration (Cmax) typically reached approximately 3 hours after the oral ingestion. The medication's bioavailability experiences a 40% reduction when administered with food. Zafirlukast requires 2 to 6 weeks for optimal efficacy and maintains a half-life of 8 to 16 hours, with an average of 10 hours.&#x000a0;</p>
        <p>Distribution: Zafirlukast demonstrates an extensive plasma protein binding rate of 99%. The drug primarily binds to albumin. A volume of distribution of 70 L indicates a moderate level of tissue distribution. In preclinical studies, zafirlukast displayed minimal penetration across the blood-brain barrier.</p>
        <p>Metabolism: Zafirlukast undergoes primary hepatic metabolism mediated by CYP2C9 enzymes.<xref ref-type="bibr" rid="article-42999.r8">[8]</xref></p>
        <p>Elimination: Zafirlukast has an oral clearance of approximately 20 L/h. Preclinical investigations indicate that the primary route of excretion is through the biliary pathway. Approximately 10% of the administered dose is excreted in urine following oral ingestion, while most are eliminated in feces.<xref ref-type="bibr" rid="article-42999.r9">[9]</xref></p>
      </sec>
      <sec id="article-42999.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Zafirlukast is available in tablet formulations with dosages available in strengths of 10 mg and 20 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Zafirlukast's bioavailability experiences a 40% reduction when administered with food. Therefore, physicians recommend taking the medication on an empty stomach, either at least 1 hour before or 2 hours after a meal. The chewable zafirlukast tablets contain a maximum of 0.842 mg of phenylalanine.<xref ref-type="bibr" rid="article-42999.r9">[9]</xref><xref ref-type="bibr" rid="article-42999.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>For managing chronic asthma, zafirlukast should be administered to patients on an empty stomach twice daily, with a 10- to 12-hour interval, considering the drug's half-life of 8 to 16 hours. The recommended dosage&#x000a0;of zafirlukast for&#x000a0;chronic asthma is 20 mg twice daily, applicable to adults and children aged 12 or older.<xref ref-type="bibr" rid="article-42999.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>Zafirlukast requires 2 to 6 weeks to attain its optimal efficacy and does not promptly reverse acute bronchospasm. Therefore, zafirlukast&#x000a0;should not be used for acute asthma exacerbations or status asthmaticus.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>In cases of asthma accompanied by allergic rhinitis, administering 20 mg of zafirlukast twice daily for 2 weeks has improved symptoms.<xref ref-type="bibr" rid="article-42999.r12">[12]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In cases of chronic urticaria, administering a 20 mg dosage of&#x000a0;zafirlukast twice daily for 3&#x000a0;to 6 weeks has demonstrated enhanced outcomes.<xref ref-type="bibr" rid="article-42999.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>For exercise-induced asthma, administering&#x000a0;a dosage of 20 mg of&#x000a0;zafirlukast twice daily for 2 weeks has been shown to prevent exercise-induced bronchospasm&#x000a0;within 8 hours of dosing.<xref ref-type="bibr" rid="article-42999.r14">[14]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Renal impairment: Dosage adjustment for patients with renal disease is not necessary with zafirlukast.</p>
        <p>Hepatic impairment: Zafirlukast usage is not recommended for patients with hepatic impairment due to compromised hepatic clearance, resulting in a 50% to 60% increase in the maximum plasma concentration.<xref ref-type="bibr" rid="article-42999.r15">[15]</xref> For patients aged 65&#x000a0;or older, hepatic clearance might be reduced, necessitating the monitoring of therapy and liver function tests.</p>
        <p>Pregnancy considerations: Zafirlukast is a Pregnancy Category B drug based on reassuring animal studies and the absence of significant evidence of major fetal malformations in humans.<xref ref-type="bibr" rid="article-42999.r16">[16]</xref><xref ref-type="bibr" rid="article-42999.r17">[17]</xref></p>
        <p>Breastfeeding considerations: Although data on zafirlukast during breastfeeding is limited, the manufacturer's labeling indicates that the concentration of zafirlukast in breast milk is low. Consequently, if the mother necessitates zafirlukast therapy, breastfeeding does not warrant discontinuing the medication. Nevertheless, considering alternatives might be advisable, particularly when nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-42999.r18">[18]</xref></p>
        <p>Pediatric patients: Zafirlukast's safety and efficacy have not been established for children younger than 5. For children between the ages of 5&#x000a0;and 11, the recommended zafirlukast dosage is 10 mg, administered&#x000a0;twice daily. Clinical data regarding zafirlukast's safety in children younger than 5 is insufficient, rendering its usage inappropriate for this age group.<xref ref-type="bibr" rid="article-42999.r19">[19]</xref><xref ref-type="bibr" rid="article-42999.r11">[11]</xref></p>
        <p>Older patients: As previously mentioned, zafirlukast demonstrates diminished clearance in individuals aged 65 or older, leading to heightened exposure (AUC) compared to younger adults. Therefore, caution must be exercised when using&#x000a0;zafirlukast in this patient population due to the increased potential for adverse drug reactions.</p>
      </sec>
      <sec id="article-42999.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Researchers have examined the adverse effects of zafirlukast in adults and children aged 12 or older. Occasional reports of eosinophilia accompanied by vasculitis in patients on zafirlukast have emerged. Consequently, instances of eosinophilia, rash, aggravated asthma, cardiac problems, and neuropathy should prompt a thorough investigation.</p>
        <p>Over 100&#x000a0;cases of severe hepatic failure have been reported, which show their association with zafirlukast usage. Hepatitis signs, such as right upper quadrant pain, jaundice, and pruritus, should prompt the monitoring of transaminases. If there is clinical suspicion of hepatotoxic effects, the drug usage should be discontinued. In most instances, the discontinuation of zafirlukast results in the resolution of transaminase levels. Nevertheless, in rare scenarios, patients have exhibited fulminant hepatitis, leading to hepatic failure, liver transplantation, and even death. Under such circumstances, the reattempt of zafirlukast administration prompts swift recurrence and must be strictly avoided.<xref ref-type="bibr" rid="article-42999.r20">[20]</xref></p>
        <p>Furthermore, neuropsychiatric events such as depression and insomnia have been documented, necessitating clinicians to instruct patients to promptly report any related symptoms associated with the adverse effects of the medication. Moreover, reports have indicated an increased incidence of respiratory tract infections in patients aged 55 or older.</p>
        <p>Common adverse drug reactions of&#x000a0;zafirlukast include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (10%), dizziness, neuropathy, hallucinations, insomnia, depression,&#x000a0;and abnormal dreams.<xref ref-type="bibr" rid="article-42999.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Nausea (3%), diarrhea (3%), abdominal pain (3%), vomiting, and&#x000a0;dyspepsia.<xref ref-type="bibr" rid="article-42999.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Transaminase elevation (aspartate transaminase/&#x000a0;alanine aminotransferase), symptomatic hepatitis, hyperbilirubinemia, fulminant hepatitis, and progressive hepatic failure.<xref ref-type="bibr" rid="article-42999.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Myalgia, back pain, arthralgia, theophylline toxicity symptoms, edema,&#x000a0;and&#x000a0;malaise.<xref ref-type="bibr" rid="article-42999.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Pain (2%), asthenia (2%), injury, and fever.<xref ref-type="bibr" rid="article-42999.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Respiratory tract infection in patients 55 or older with coadministration of inhaled corticosteroids (3%)</p>
          </list-item>
          <list-item>
            <p>Menorrhagia, thrombocytopenia, alopecia, bruising, pruritis, urticaria, angioedema, and&#x000a0;rashes.<xref ref-type="bibr" rid="article-42999.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Granulomatosis, agranulocytosis, eosinophilia, eosinophilic pneumonia, and Churg-Strauss-related syndrome.<xref ref-type="bibr" rid="article-42999.r24">[24]</xref><xref ref-type="bibr" rid="article-42999.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>Zafirlukast is a CYP2CP9 substrate and weak&#x000a0;inhibitor, which&#x000a0;may interact with or decrease concentrations of alpelisib (kinase inhibitor), dabrafenib, enzalutamide, lumacaftor, ivacaftor, and rifapentine. Erythromycin and theophylline can decrease the concentration of zafirlukast. Aspirin can elevate the concentration of zafirlukast. Combining inhaled loxapine with zafirlukast should be avoided to mitigate the heightened risk of bronchospasm. The concomitant use of zafirlukast and warfarin can result in an elevation of the international normalized ratio (INR), necessitating diligent monitoring to ensure optimal control of coagulability.<xref ref-type="bibr" rid="article-42999.r9">[9]</xref><xref ref-type="bibr" rid="article-42999.r10">[10]</xref>&#x000a0;</p>
        <p>A recent study highlights that concurrent administration of tizanidine and zafirlukast could lead to hypotension, potentially elevating the risk of falls and fractures.<xref ref-type="bibr" rid="article-42999.r26">[26]</xref></p>
      </sec>
      <sec id="article-42999.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Zafirlukast is contraindicated in individuals with a history of hypersensitivity reactions to the active drug component and the inactive compounds within the formulation, including povidone, lactose, titanium dioxide, or cellulose. Zafirlukast is further contraindicated in patients with cirrhosis and hepatic impairment due to case reports indicating a risk of hepatic failure.<xref ref-type="bibr" rid="article-42999.r15">[15]</xref></p>
      </sec>
      <sec id="article-42999.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients with chronic asthma require&#x000a0;regular monitoring to track improvements in pulmonary function tests as a response to zafirlukast&#x000a0;treatment. For patients displaying indications of hepatic injury, monitoring of transaminases and bilirubin is imperative to detect adverse events of the drug promptly. Often, discontinuing the medication can lead to the resolution of mild liver injury. Patients concurrently taking zafirlukast and warfarin may experience an elevation in the INR, necessitating vigilant monitoring.<xref ref-type="bibr" rid="article-42999.r20">[20]</xref></p>
      </sec>
      <sec id="article-42999.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinical studies have documented that at high doses of 80 mg, zafirlukast can elevate transaminase levels.<xref ref-type="bibr" rid="article-42999.r27">[27]</xref> Animal studies have shown that zafirlukast doses of 500 mg/kg in dogs and 2000 mg/kg in mice did not result in any reported deaths.&#x000a0;According to&#x000a0;manufacturer guidelines, 4 reported drug overdose cases in patients survived with 200 mg of zafirlukast. These cases exhibited mild symptoms, including rash and upset stomach. In cases of acute zafirlukast overdose, the recommended intervention for patients includes gastric lavage, vigilant clinical monitoring, and supportive therapy.<xref ref-type="bibr" rid="article-42999.r28">[28]</xref></p>
      </sec>
      <sec id="article-42999.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Zafirlukast was&#x000a0;approved by the FDA for asthma treatment in the United States in 1996, and it continues to be a widely used drug, with over 2 million prescriptions being dispensed annually. Effective management of chronic asthma necessitates the collaborative efforts of an interprofessional team consisting of clinicians, pharmacists, laboratory technologists, and various healthcare providers. Asthma affects approximately 25 million individuals in the United States, with 7.7% of adults and 8.4% of children within reach.<xref ref-type="bibr" rid="article-42999.r29">[29]</xref>&#x000a0;</p>
        <p>The&#x000a0;National Surveillance for Asthma suggests that LTRAs, such as zafirlukast, can serve as an alternative or adjunct to inhaled corticosteroids within the stepwise approach for individuals necessitating a second or third treatment option due to insufficient progress.<xref ref-type="bibr" rid="article-42999.r30">[30]</xref>&#x000a0;</p>
        <p>Zafirlukast is frequently prescribed in outpatient settings for cases of chronic asthma that remain uncontrolled or are unresponsive to short-acting beta-agonists and inhaled corticosteroids. Given its delayed peak effect over several weeks, regular follow-up with healthcare providers is crucial to oversee pulmonary function and track symptomatic enhancements. The interprofessional team comprising clinicians, specialists, nurses, respiratory therapists, and pharmacists is essential in coordinating and delivering comprehensive patient care, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Scheduling follow-up appointments to evaluate improvements</p>
          </list-item>
          <list-item>
            <p>Monitoring INR in patients on warfarin concurrently using zafirlukast</p>
          </list-item>
          <list-item>
            <p>Monitoring liver function tests in patients with reduced hepatic function or clearance</p>
          </list-item>
          <list-item>
            <p>Monitoring for signs of allergic reactions related to the medication, eosinophilic vasculitis, neuropsychiatric complaints, and hepatic dysfunction</p>
          </list-item>
          <list-item>
            <p>Consulting a pulmonologist or allergy specialist for managing chronic severe asthma</p>
          </list-item>
          <list-item>
            <p>Consulting with a pharmacist to ensure safe usage in conjunction with other medications</p>
          </list-item>
          <list-item>
            <p>Collaborating with multiple inpatient and outpatient teams to&#x000a0;effectively manage acute asthma exacerbations</p>
          </list-item>
          <list-item>
            <p>Staying updated on current guidelines, including GINA guidelines, for delivering patient-centered care effectively.<xref ref-type="bibr" rid="article-42999.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Adhering to evidence-based guidelines like those provided by the National Asthma Education and Prevention Program Coordinating Committee Expert Panel (NAEPP) in collaboration with the National Heart, Lung, and Blood Institute. The collective aim of the healthcare teams is to enhance patient care and facilitate well-informed choices regarding asthma management.<xref ref-type="bibr" rid="article-42999.r31">[31]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Any interprofessional team member who identifies the abovementioned concerns, additional adverse effects, or treatment inefficacies should document their observations in the patient's medical record and communicate the information to the entire team to implement appropriate corrective measures.&#x000a0;Utilizing a collaborative interprofessional approach that emphasizes open communication, information sharing, and shared decision-making between healthcare providers and patients will enhance the therapeutic results of zafirlukast therapy, leading to reduced adverse events of the drug.</p>
      </sec>
      <sec id="article-42999.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42999&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42999">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42999/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42999">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-42999.s11">
        <fig id="article-42999.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Zafirlukast Mechanism of Action, Indications, and Contraindications. Contributed by Amareen Dhaliwal</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__2020-06-02__at__5.44.04__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-42999.s12">
        <title>References</title>
        <ref id="article-42999.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Azmat</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <chapter-title>Leukotriene Receptor Antagonists</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32119332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dempsey</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>Leukotriene receptor antagonist therapy.</article-title>
            <source>Postgrad Med J</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>902</issue>
            <fpage>767</fpage>
            <page-range>767-73</page-range>
            <pub-id pub-id-type="pmid">11085767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddel</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Bacharier</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Brightling</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Buhl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Duijts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drazen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mortimer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pitrez</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yorgancioglu</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Boulet</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.</article-title>
            <source>Eur Respir J</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34667060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Zafirlukast inhibits the growth of lung adenocarcinoma via inhibiting TMEM16A channel activity.</article-title>
            <source>J Biol Chem</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>298</volume>
            <issue>3</issue>
            <fpage>101731</fpage>
            <pub-id pub-id-type="pmid">35176281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montuschi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Role of Leukotrienes and Leukotriene Modifiers in Asthma.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Jun</month>
            <day>02</day>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>1792</fpage>
            <page-range>1792-1811</page-range>
            <pub-id pub-id-type="pmid">27713330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirois</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Leukotrienes: One step in our understanding of asthma.</article-title>
            <source>Respir Investig</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-110</page-range>
            <pub-id pub-id-type="pmid">30600174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laitinen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindqvist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halme</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altraja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laitinen</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-65</page-range>
            <pub-id pub-id-type="pmid">15696079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savidge</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Birmingham</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Morse</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Spreen</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Metabolism and excretion of zafirlukast in dogs, rats, and mice.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>1069</fpage>
            <page-range>1069-76</page-range>
            <pub-id pub-id-type="pmid">9806948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dekhuijzen</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Koopmans</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic profile of zafirlukast.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2002</year>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-14</page-range>
            <pub-id pub-id-type="pmid">11888331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adkins</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.</article-title>
            <source>Drugs</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>121</fpage>
            <page-range>121-44</page-range>
            <pub-id pub-id-type="pmid">9463793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendeles</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dose selection and dosing interval determination for LTRA use in asthma.</article-title>
            <source>Postgrad Med</source>
            <year>2000</year>
            <month>Sep</month>
            <day>15</day>
            <volume>108</volume>
            <issue>4 Suppl</issue>
            <fpage>12</fpage>
            <page-range>12-21</page-range>
            <pub-id pub-id-type="pmid">19667530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ceriotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cavallaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mantovani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pistone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Centanni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of zafirlukast on bronchial asthma and allergic rhinitis.</article-title>
            <source>Pharmacol Res</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>541</fpage>
            <page-range>541-7</page-range>
            <pub-id pub-id-type="pmid">12742009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Generali</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cada</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Zafirlukast: Chronic Urticaria.</article-title>
            <source>Hosp Pharm</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>873</fpage>
            <page-range>873-875</page-range>
            <pub-id pub-id-type="pmid">27729674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dessanges</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pr&#x000e9;faut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taytard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naya</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Compagnon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dinh-Xuan</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>1155</fpage>
            <page-range>1155-61</page-range>
            <pub-id pub-id-type="pmid">10588995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wooltorton</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Asthma drug zafirlukast (Accolate): serious hepatic events.</article-title>
            <source>CMAJ</source>
            <year>2004</year>
            <month>May</month>
            <day>25</day>
            <volume>170</volume>
            <issue>11</issue>
            <fpage>1668</fpage>
            <pub-id pub-id-type="pmid">15159361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonham</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Strek</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Asthma Outcomes and Management During&#x000a0;Pregnancy.</article-title>
            <source>Chest</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>153</volume>
            <issue>2</issue>
            <fpage>515</fpage>
            <page-range>515-527</page-range>
            <pub-id pub-id-type="pmid">28867295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <collab>National Heart, Lung, and Blood Institute</collab>
            <collab>National Asthma Education and Prevention Program Asthma and Pregnancy Working Group</collab>
            <article-title>NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-46</page-range>
            <pub-id pub-id-type="pmid">15637545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Zafirlukast</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30000549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearlman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lampl</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bonuccelli</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>732</fpage>
            <page-range>732-47</page-range>
            <pub-id pub-id-type="pmid">10929920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Zafirlukast</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>6</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">31643251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McQueen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Churg-Strauss vasculitis syndrome and leukotriene receptor antagonists.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>1382</fpage>
            <pub-id pub-id-type="pmid">16100351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelloway</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.</article-title>
            <source>Ann Pharmacother</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>1012</fpage>
            <page-range>1012-21</page-range>
            <pub-id pub-id-type="pmid">9296243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Vitis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Severe liver injury associated with zafirlukast.</article-title>
            <source>Ann Intern Med</source>
            <year>2001</year>
            <month>Nov</month>
            <day>20</day>
            <volume>135</volume>
            <issue>10</issue>
            <fpage>930</fpage>
            <pub-id pub-id-type="pmid">11712893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>150</volume>
            <issue>3</issue>
            <fpage>618</fpage>
            <page-range>618-23</page-range>
            <pub-id pub-id-type="pmid">8087328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haarman</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>van Hunsel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Adverse drug reactions of montelukast in children and adults.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">28971612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villa-Zapata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Lumbreras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).</article-title>
            <source>Drug Saf</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>863</fpage>
            <page-range>863-871</page-range>
            <pub-id pub-id-type="pmid">35834155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Zafirlukast (Accolate).</article-title>
            <source>Drugs Today (Barc)</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>375</fpage>
            <page-range>375-88</page-range>
            <pub-id pub-id-type="pmid">15010725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cantilena</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rumack</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Giffin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>911</fpage>
            <page-range>911-1084</page-range>
            <pub-id pub-id-type="pmid">20028214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheehan</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Phipatanakul</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Difficult-to-control asthma: epidemiology and its link with environmental factors.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>397</fpage>
            <page-range>397-401</page-range>
            <pub-id pub-id-type="pmid">26226354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarter</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Asthma-The National Surveillance Data and the National Asthma Education and Prevention Program's Expert Panel Report 3.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>35</fpage>
            <page-range>35-50</page-range>
            <pub-id pub-id-type="pmid">25126216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42999.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)</collab>
              <name>
                <surname>Cloutier</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Baptist</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Bryant-Stephens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DiMango</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Elward</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Hartert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lemanske</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Ouellette</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Teach</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Umscheid</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>2020 Focused Updates to the Asthma Management Guidelines: A&#x000a0;Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>1217</fpage>
            <page-range>1217-1270</page-range>
            <pub-id pub-id-type="pmid">33280709</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
